Obermatt
See Similar Stocks →

Compass Pathways

NSQ:CMPS · US20451W1018
BiotechnologySmall

360° View

29
Price/Sales3
Price/Earnings69
Price/Book5
Dividend Yield1
Revenue Growth—
Profit Growth23
Capital Growth11
TSR 52w91
Leverage54
Liquidity29
Refinancing16
Combined6
Analyst Opinions67
Pro Holdings77
Opinion Changes92
Market Pulse17

Profile

CountryUK
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2020
Employees214
Websitecompasspathways.com
ISINUS20451W1018
Last UpdateApr 2, 2026
Index & Theme
Psychedelic-Based TherapyChronic DiseasesNeurologyCentral Nervous SystemPsychiatryBiotechnologyHealth CareLife SciencePersonal HealthWellness

Description

COMPASS Pathways plc operates as a biotechnology company. The company is dedicated to accelerating patient access to evidence-based innovation in mental health. The company is pioneering a new paradigm for treating mental health conditions, focused…

Analysis

Compass Pathways's 360° View rank of 29 places it below its peer average — better than 29% of its true peers.

It's growing slowly (48) and expensive versus peers (7). On safety it is carrying more balance-sheet risk (26), and the market shows strongly positive sentiment (93). Taken together, its Combined rank of 6 reads as among the weakest overall.

360° rank · history

1007550250
29
2026

All-time high

35

Mar 2026

All-time low

29

Jun 2026

Average rank

32

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
3
—
—
—
Price/Earnings
69
—
—
—
Price/Book
5
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
7
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Compass Pathways with its peers
Zealand Pharma
CPH:ZEAL
78
CountryDenmark
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Valneva
PAR:VLA
21
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Urogen Pharma
NMQ:URGN
31
CountryIsrael
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Uniqure
NSQ:QURE
20
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Transgene
PAR:TNG
15
CountryFrance
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Tiziana Life Sciences
NAQ:TLSA
67
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →